Lucy Boulter, Legal Representative

Title: The Innovative Contributions of Lucy Boulter

Introduction

Lucy Boulter is a distinguished legal representative and inventor based in Oxfordshire, GB. She has made significant contributions to the field of immunology through her innovative patents. With a total of three patents to her name, Boulter is recognized for her work in developing high-affinity T cell receptors.

Latest Patents

Boulter's latest patents focus on high-affinity NY-ESO T cell receptors. The first patent provides T cell receptors (TCRs) that bind to SLLMWITQC-HLA-A*0201, with the peptide derived from the NY-ESO-1 protein, which is expressed by various tumor cells. These TCRs exhibit a K value for the peptide-HLA complex of less than or equal to 1 µM and an off-rate (k) of 1×10⁻⁵ or slower. The second patent reiterates similar findings, emphasizing the importance of these TCRs in targeting tumor cells effectively.

Career Highlights

Boulter is currently associated with Immunocore Limited, a company that specializes in developing innovative therapies for cancer treatment. Her expertise in legal representation complements her role as an inventor, allowing her to navigate the complexities of patent law effectively.

Collaborations

Some of her notable coworkers include Steven Mark Dunn and Yi Li, who contribute to the collaborative environment at Immunocore Limited. Their combined efforts enhance the research and development of groundbreaking therapies.

Conclusion

Lucy Boulter's work exemplifies the intersection of legal expertise and scientific innovation. Her contributions to the field of immunology through her patents are paving the way for advancements in cancer treatment.